Find information on thousands of medical conditions and prescription drugs.

Cardiomyopathy

Cardiomyopathy is the deterioration of the cardiac muscle of the heart wall. Cardiomyopathy can lead to heart failure as the pumping efficiency of the heart is diminished. People with cardiomyopathy are often at risk of arrhythmia and/or sudden cardiac death. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Cardiomyopathies can generally be categorized into two groups: ischemic cardiomyopathy and nonischemic cardiomyopathy.

Ischemic

Ischemic cardiomyopathy is weakness in the muscle of the heart due to coronary artery disease. Individuals with ischemic cardiomyopathy typically have a history of myocardial infarction (heart attack).

Nonischemic

Nonischemic cardiomyopathy is weakness in the muscle of the heart that is not due to coronary artery disease. To make a diagnosis of nonischemic cardiomyopathy, significant coronary artery disease should be ruled out. The term nonischemic cardiomyopathy does not describe the etiology of weakened heart muscle. The nonischemic cardiomyopathies are a mixed-bag of disease states, each with their own causes.

Nonischemic cardiomyopathy has a number of causes including drug and alcohol toxicity, certain infections (including Hepatitis C), and various genetic and idiopathic (i.e. unknown) causes.

Nonischemic subtypes

There are four main types of nonischemic cardiomyopathy:

  • Dilated cardiomyopathy (DCM), the most common form of cardiomyopathy, and one of the leading indications for heart transplantation. In DCM the heart (especially the left ventricle) is enlarged and weakened. Approximately 40% of cases are familial, but the genetics are poorly understood compared with HCM. In some cases it manifests as peripartum cardiomyopathy, and in other cases it may be associated with alcoholism.
  • Hypertrophic cardiomyopathy (HCM or HOCM), a genetic disorder caused by various mutations in genes encoding sarcomeric proteins. In HCM the heart muscle is thickened, which can obstruct blood flow and prevent the heart from functioning properly.
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC) arises from an electrical disturbance of the heart in which heart muscle is replaced by fibrous scar tissue. The right ventricle is generally most affected.
  • Restrictive cardiomyopathy (RCM) is the least common cardiomyopathy. The walls of the ventricles are stiff, but may not be thickened, and resist the normal filling of the heart with blood. A rare form of restrictive cardiomyopathy is the obliterative cardiomyopathy, seen in the hypereosinophilic syndrome. In this type of cardiomyopathy, the myocardium in the apicies of the left and right ventricles become thickened and fibrotic, causing a decrease in the volumes of the ventricles and a type of restrictive cardiomyopathy.

Treatment

Treatment depends on the type of cardiomyopathy, but may include medical therapy and implanted artificial pacemakers. The goal of treatment is often symptom relief, with the underlying condition unaffected. Some patients may eventually require a heart transplant. Treatment of cardiomyopathy (and other heart diseases) using alternative methods such as stem cell therapy is commercially available but is not supported by convincing evidence.

Read more at Wikipedia.org


[List your site here Free!]


Myocardial apoptotic index based on in situ DNA nick end-labeling of endomyocardial biopsies does not predict prognosis of dilated cardiomyopathy
From CHEST, 8/1/05 by Hideshi Okada

Background: DNA breaks detected largely by terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate in situ nick end-labeling (TUNEL) are observed in the hearts of patients with diseases such as dilated cardiomyopathy (DCM).

Study objectives: To determine the prognostic value of TUNEL assays in cases of DCM.

Design, setting, and participants: DCM patients were selected from among patients who had undergone left ventricular (LV) biopsy during the period from 1994 to 2001 in our hospital. Of those, 46 (35 men and 11 women; mean [[+ or -] SD] age, 58 [+ or -] 11 years) who were followed up for > 3 years after the undergoing the biopsy (mean follow-up period, 4.9 [+ or -] 2.0 years) or died during the follow-up period were entered into the present study. The myocardial apoptotic index was assessed in deparaffinized biopsy specimens that were stained using a conventional TUNEL assay. In addition, all surviving patients received a follow-up echocardiographic examination.

Results: Ten of the 46 biopsy specimens (22%) contained TUNEL-positive myocytes; their mean apoptotic index was 0.44 [+ or -] 1.05%. The apoptotic index showed no relation to cardiac functional parameters determined at the time of biopsy, however. Seven patients died during the follow-up period, and 19 of the surviving patients were readmitted to the hospital because of a worsening of their heart failure. There was no significant difference in the apoptotic indexes of biopsy specimens from the dead and surviving patients, or between the surviving patients who were readmitted to the hospital and those who were not. There was also no significant correlation between the apoptotic index and changes in the LV ejection fraction, LV end-diastolic diameter, or LV posterior wall thickness during follow-up.

Conclusion: The apoptotic index derived from TUNEL assays is not predictive of the prognosis of patients with DCM-induced heart failure.

Key words: apoptosis; heart failure; dilated cardiomyopathy; prognosis

Abbreviations: CHF = congestive heart failure; DCM = dilated cardiomyopathy; LV = left ventricle, ventricular; LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; LVPWT = left ventricular posterior wall thickness; TUNEL = terminal deoxynudeotidyltransferase-mediated deoxyuridine triphosphate in situ nick end-labeling

**********

DNA breaks detected largely by terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate in situ nick end-labeling (TUNEL) have been observed in the hearts of patients with diseases such as dilated cardiomyopathy (DCM). (1,2) This suggests that the loss of cardiac myocytes due to apoptosis may contribute to the progression of congestive heart failure (CHF), though so far the data are inconclusive. (3,4) If correct, however, the level of apoptosis within the myocardium may influence the prognosis of CHF patients; in other words, the apoptotic index measured in specimens of myocardial tissue may have predictive value as to patient outcome. To test this hypothesis, we carried out a tracking study in a group of DCM patients who had undergone endomyocardial biopsy > 3 years earlier and were followed up thereafter.

MATERIALS AND METHODS

After obtaining approval for this study from our local ethics committees, patients with DCM diagnosed according to the definition and classification proposed by the World Health Organization/International Society and Federation of Cardiology task force were selected from among those who had undergone left ventricular (LV) biopsy in our hospital during the period from 1994 to 2001. Of those, 46 patients who were followed up for > 3 years after the biopsy (mean [ [+ or -] SD] follow-up period, 4.9 [+ or -] 2.0 years) or died during the follow-up period were entered into the present study. These participants included 35 men and 11 women with a mean age of 58 years (age range, 23 to 75 years). The endomyocardial biopsy specimens were obtained from the posterior free wall of the LV, and the myocardial apoptotic index was determined in deparaffinized biopsy specimens that were stained using a conventional TUNEL assay. (5) In each specimen, a mean of 276 [+ or -] 66 cardiomyocytes were evaluated within a mean area of 1.4 [+ or -] 0.5 [mm.sup.2]. In addition, the sections were subjected to Taq polymerase-based in situ ligation assays using a method previously described. (6) We also examined the specimens under an electron microscope, observing at least five grids from each case.

RESULTS AND DISCUSSION

The biopsy specimens from 10 of the 46 patients (22%) contained TUNEL-positive myocytes; the mean apoptotic index was 0.44 [+ or -] 1.05%. However, the apoptotic index was found to have no relation to any functional parameters or to the anatomic status of the hearts, which were assessed at biopsy by cardiac catheterization (ie, LV pressures, LV ejection fraction [LVEF], and LV end-diastolic volume index) and echocardiography (LVEF and LV dimensions, including LV end-diastolic diameter [LVEDD], and LV posterior wall thickness [LVPWT]) [Table 1]. In addition, the results of the Taq polymerase-based in situ DNA ligation assays were negative in all biopsy specimens, although, as expected, positive reactions were noted in lining epithelial cells from mouse thymus tissue (ie, the positive control). Using the electron microscope, we failed to find even one myocyte showing the typical ultrastructural features of apoptosis in any of the specimens. These patients were treated with digitalis, diuretics, vasodilators, or some combination of the three, but there was no specific difference in the medication used between patients whose biopsy specimens were TUNEL-positive and those that were not.

We also tested whether the apoptotic index derived from the TUNEL assays could reflect the patients' prognosis with respect to survival or progression of the CHF. Seven patients died during the follow-up period, and 19 of the surviving patients were readmitted to hospitals due to a worsening of their CHF. The biopsy specimen from one of the dead patients was TUNEL-positive, but the other six were not. Moreover, there was no significant difference between the apoptotic indexes of the biopsy specimens from dead and surviving patients (0.38 [+ or -] 1.00% vs 0.45 [+ or -] 1.08%, respectively; p = 0.87), or between the surviving patients who were readmitted to the hospital and those who were not (0.40 [+ or -] 0.95% vs 0.55 [+ or -] 1.21%, respectively; p = 0.55).

All surviving patients received a follow-up echocardiographic examination. Earlier echocardiography findings showed that at biopsy the mean LVEF was 40.9. [+ or -] 11.3%, the mean LVEDD was 60.6 [+ or -] 6.7 min, and the mean LVPWT was 9.7 [+ or -] 1.6 mm. Over the course of the > 3-year follow-up period (mean follow-up period, 4.9 [+ or -] 2.0 years), changes in these functional parameters were small. LVEF increased by about 11.7% to 44.9 [+ or -] 14.0%, while LVEDD and LVPWT stayed about the same (60.5 [+ or -] 9.6 and 9.7 [+ or -] 1.4 mm, respectively). There was no significant correlation between the apoptotic index and changes in these functional parameters (Fig 1).

[FIGURE 1 OMITTED]

The present data clearly do not support the hypothesis that conventional TUNEL assays of endomyocardial biopsy specimens from patients with DCM-induced CHF have prognostic value with respect to either survival or the functional status of the heart. But because LV endomyocardial biopsy specimens represent only a small part of the LV, they do not exclude the possibility that the presence or absence of apoptosis in other parts of the LV could reflect in vivo status. Having said that, however, the high proportion of TUNEL-positive cells reported in earlier studies (1,2,3,6) that analyzed whole hearts might lead one to expect that the affected patients inevitably died in short order, but that does not fit with the clinical observations. More importantly, to our knowledge, there has never been a report identifying cardiomyocytes with the characteristic apoptotic ultrastructure in DCM patients, (6) which we also failed to see in the present study. Still, TUNEL assays measure only a small portion of the total apoptotic cascade, and a biopsy study including electron microscopy records only a tiny segment of time during the course of a disease that stretches over decades, leaving open the possibility that apoptosis may not be rare in patients with DCM.

Bearing these findings in mind, along with the known limitations of the TUNEL assay (eg, its lack of specificity), we suggest that TUNEL assays cannot be used as the sole test to identify apoptosis in failing hearts, as the derived apoptotic indexes are not predictive of the prognosis of DCM-induced CHF.

REFERENCES

(1) Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335:1182-1189

(2) Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336:1131-1141

(3) Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res 2000; 86:1107-1113

(4) Elsasser A, Suzuki K, Schaper J. Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure. J Mol Cell Cardiol 2000; 32:711-724

(5) Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119:493-501

(6) Didenko VV, Hornsby PJ. Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis. J Cell Biol 1996; 135:1369-1376

Manuscript received December 25, 2004; revision accepted March 23, 2005.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtml).

Correspondence to: Hisayoshi Fujiwara, MD, PhD, Second Department of Internal Medicine, Gifu University School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan; e-mail: gifuimgif@umin.ac.jp

* From the Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan.

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Cardiomyopathy
Home Contact Resources Exchange Links ebay